22.57
-1.13(-4.77%)
Currency In USD
| Previous Close | 23.7 |
| Open | 23.75 |
| Day High | 23.76 |
| Day Low | 22.43 |
| 52-Week High | 45.3 |
| 52-Week Low | 20.21 |
| Volume | 2.28M |
| Average Volume | 1.99M |
| Market Cap | 2.08B |
| PE | -17.63 |
| EPS | -1.28 |
| Moving Average 50 Days | 26.22 |
| Moving Average 200 Days | 32.33 |
| Change | -1.13 |
If you invested $1000 in Legend Biotech Corporation (LEGN) since IPO date, it would be worth $610 as of January 14, 2026 at a share price of $22.57. Whereas If you bought $1000 worth of Legend Biotech Corporation (LEGN) shares 5 years ago, it would be worth $765.08 as of January 14, 2026 at a share price of $22.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Exceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest co
Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
GlobeNewswire Inc.
Nov 27, 2025 2:00 PM GMT
Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as a global biotech hub SOMERSET, N.J. and GHENT, Belgium, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Lege